Asset Assessment and Clinical Strategy Diligence for BD Decision-Making

Situation

Client needed ongoing assessment of external assets for acquisition or partnership potential.
Required a structured view of each asset’s scientific, clinical, strategic, and commercial viability to inform executive go / no-go decisions.
Needed to understand both the quality of the current development approach and the asset’s future value potential.

Conducted end-to-end asset assessments spanning preclinical data, clinical evidence, and development strategy to identify strengths, risks, and gaps.
Developed net-new clinical and evidence-generation strategies to assess future development pathways and value creation opportunities.
Built financial models to size the opportunity, including patient funnel, addressable population, uptake, and ROI potential.
Synthesized scientific, clinical, and commercial findings into an executive-level recommendation on asset attractiveness.

Enabled leadership to make more informed acquisition and partnering decisions.
Identified key risks and value-creation levers across asset development and evidence strategy.
Provided an integrated view of clinical potential and commercial upside to support go / no-go investment decisions.